Preliminary assessment suggested that GHRP‑2 was not a relevant confounding factor for the FN1 and RAB31 biomarkers of rhGH administration.
In plain wordsA preliminary check suggested that GHRP‑2 did not interfere with blood markers used to detect growth hormone abuse.
- Peptide
- GHRP-2
- Outcome
- No significant changeInfluence of GHRP-2 on rhGH abuse biomarkers
- Study
n: not reported in source
- Outcome group
- Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Preliminary assessments of gender, age, acute sport activities and GHRP-2 (pralmorelin, a rhGH releasing peptide) influence suggest they are not relevant confounding factors.
1 context sentence(design, population, supporting numbers)
Following this line, in the present study some genetic and proteomic approaches have been performed with fourteen healthy male subjects treated with rhGH (which produces increase of IGF-1 concentrations) to study FN1 gene, FN1 protein, RAB31 gene and RAB31 protein as potential biomarkers for rhGH abuse.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.